NCT06456268 VibraCool Device to Reduce Pain and Opioid Use After Anterior Cruciate Ligament Reconstruction (ACLR)
| NCT ID | NCT06456268 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | ACL |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2026-06 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 130 participants in total. It began in 2026-06 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this project is to test the effects of the VibraCool mechanical stimulation neuromodulatory therapeutic device on post-operative pain and opioid use following anterior crucitate ligament reconstruction (ACLR), and thus residual opioids in circulation.
Eligibility Criteria
Inclusion Criteria: * Underwent ACL reconstruction Exclusion Criteria: * Pediatric iliotibial band ACL reconstruction (known to cause significantly more pain) * Non-english speakers (limitations of our study group)
Frequently Asked Questions
Who can join the NCT06456268 clinical trial?
This trial is open to participants of all sexes, studying ACL. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06456268 currently recruiting?
Yes, NCT06456268 is actively recruiting participants. Visit ClinicalTrials.gov or contact Columbia University to inquire about joining.
Where is the NCT06456268 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06456268 clinical trial?
NCT06456268 is sponsored by Columbia University. The trial plans to enroll 130 participants.